Upvote Story 3

Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome

Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome

Current pharmacologic treatment of the neonatal abstinence syndrome with morphine is associated with a lengthy duration of therapy and hospitalization. Buprenorphine may be more effective than morphine for this indication. Among infants with the neonatal abstinence syndrome, treatment with sublingual buprenorphine resulted in a shorter duration of treatment and shorter length of hospital stay than treatment with oral morphine, with similar rates of adverse events

CriticalCare.news
May 12, 2017

Related Books

Leave Your Comment